@article{813768a6a94046a1ac1787b7201453e9,
title = "Patient Selection for Mepolizumab in Severe Asthma: Time for Reappraisal?",
author = "Hannu Kankaanranta and Pinja Ilmarinen",
note = "Funding Information: This study was supported by Tampere Tuberculosis Foundation and the Finnish Anti-Tuberculosis Foundation and the Competitive State Research Financing of the Expert Responsibility Area of Tampere University Hospital (Tampere, Finland). Funding Information: Conflicts of interest: H. Kankaanranta reports grants, personal fees, and nonfinancial support from AstraZeneca , personal fees and nonfinancial support from Boehringer-Ingelheim, personal fees from Chiesi Pharma AB, personal fees from GlaxoSmithKline, personal fees from MSD, personal fees from Mundipharma, personal fees from Novartis, personal fees from Orion Pharma, and personal fees from SanofiGenzyme, outside the submitted work. P. Ilmarinen reports grants and personal fees from AstraZeneca , personal fees from Mundipharma, personal fees from GlaxoSmithKline, and personal fees from Novartis, outside the submitted work. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",
year = "2020",
doi = "10.1016/j.jaip.2020.05.036",
language = "English",
volume = "8",
pages = "3009--3010",
number = "9",
}